Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Fulgent Genetics to Announce Second Quarter 2017 Financial Results on August 7, 2017

Posted on: 31 Jul 17

TEMPLE CITY, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2017 financial results after the market closes on Monday, August 7, 2017. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investor section of the company’s website,, and through a live conference call by dialing (855) 321-9535 using the conference ID 55000778. An audio replay will be available in the investors section of the company’s website or by calling (855) 859-2056 using passcode 55000778 through August 14, 2017.

About Fulgent Genetics

Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

CONTACT: Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, Chris Danne, 415-217-5865, chris@blueshirtgroup.comGlobeNewswire

Last updated on: 01/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.